Literature DB >> 12424226

Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis.

Chrishan S Samuel1, Chongxin Zhao, Ross A D Bathgate, Courtney P Bond, Matthew D Burton, Laura J Parry, Roger J Summers, Mimi L K Tang, Edward P Amento, Geoffrey W Tregear.   

Abstract

Relaxin (RLX) is a peptide hormone with known antifibrotic properties. However, its significance in the lung and its role as a therapeutic agent against diseases characterized by pulmonary fibrosis are yet to be established. In this study, we examined age-related structural and functional changes in the lung of relaxin-deficient mice. Lung tissues of male and female RLX knockout (-/-) and RLX wild-type (+/+) mice at various ages were analyzed for changes in collagen expression and content. We demonstrate an age-related progression of lung fibrosis in RLX -/- mice with significantly increased tissue wet weight, collagen content and concentration, alveolar congestion, and bronchiole epithelium thickening. The increased fibrosis was associated with significantly altered peak expiratory flow and lung recoil (lung function) in RLX -/- mice. Treatment of RLX -/- mice with relaxin in early and developed stages of fibrosis resulted in the reversal of collagen deposition. Organ bath studies showed that precontracted lung strips relaxed in the presence of relaxin. Together, these data indicate that relaxin may provide a means to regulate excessive collagen deposition in diseased states characterized by pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12424226     DOI: 10.1096/fj.02-0449fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

Review 1.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 2.  Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways.

Authors:  M L Halls; E T van der Westhuizen; R A D Bathgate; R J Summers
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

3.  Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity.

Authors:  Kazuyuki Tsujino; Yoshito Takeda; Toru Arai; Yasushi Shintani; Ryosaku Inagaki; Hiroyuki Saiga; Takeo Iwasaki; Satoshi Tetsumoto; Yingji Jin; Shoichi Ihara; Toshiyuki Minami; Mayumi Suzuki; Izumi Nagatomo; Koji Inoue; Hiroshi Kida; Takashi Kijima; Mari Ito; Masanori Kitaichi; Yoshikazu Inoue; Isao Tachibana; Kiyoshi Takeda; Meinoshin Okumura; Martin E Hemler; Atsushi Kumanogoh
Journal:  Am J Respir Crit Care Med       Date:  2012-05-16       Impact factor: 21.405

Review 4.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 5.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

Review 6.  Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Authors:  Anthony J Kanai; Elisa M Konieczko; Robert G Bennett; Chrishan S Samuel; Simon G Royce
Journal:  Mol Cell Endocrinol       Date:  2019-02-14       Impact factor: 4.102

Review 7.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

8.  MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Authors:  Harinath Bahudhanapati; Jiangning Tan; Justin A Dutta; Stephen B Strock; John Sembrat; Diana Àlvarez; Mauricio Rojas; Benedikt Jäger; Antje Prasse; Yingze Zhang; Daniel J Kass
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

Review 9.  Animal models of fibrotic lung disease.

Authors:  Bethany B Moore; William E Lawson; Tim D Oury; Thomas H Sisson; Krishnan Raghavendran; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

10.  Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice.

Authors:  Jianguo Xu; Edilson T Gonzalez; Smita S Iyer; Valerie Mac; Ana L Mora; Roy L Sutliff; Alana Reed; Kenneth L Brigham; Patricia Kelly; Mauricio Rojas
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-04-09       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.